Natera, Inc. $NTRA Shares Bought by Future Fund LLC

Future Fund LLC boosted its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 39.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,301 shares of the medical research company’s stock after buying an additional 3,741 shares during the quarter. Natera accounts for about 1.1% of Future Fund LLC’s portfolio, making the stock its 23rd largest holding. Future Fund LLC’s holdings in Natera were worth $3,047,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Robinhood Asset Management LLC purchased a new position in Natera during the 4th quarter worth approximately $12,981,000. JPMorgan Chase & Co. raised its position in Natera by 9.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after buying an additional 1,003,129 shares during the last quarter. New York State Common Retirement Fund raised its position in Natera by 63.2% during the 3rd quarter. New York State Common Retirement Fund now owns 148,247 shares of the medical research company’s stock worth $23,863,000 after buying an additional 57,400 shares during the last quarter. Krilogy Financial LLC purchased a new position in Natera during the 3rd quarter worth approximately $1,323,000. Finally, Zweig DiMenna Associates LLC raised its position in Natera by 6.8% during the 3rd quarter. Zweig DiMenna Associates LLC now owns 132,500 shares of the medical research company’s stock worth $21,329,000 after buying an additional 8,400 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Natera

In related news, CFO Michael Burkes Brophy sold 482 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $210.49, for a total value of $101,456.18. Following the completion of the sale, the chief financial officer owned 57,496 shares of the company’s stock, valued at approximately $12,102,333.04. The trade was a 0.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 1,438 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $202.84, for a total transaction of $291,683.92. Following the completion of the sale, the insider directly owned 185,782 shares of the company’s stock, valued at approximately $37,684,020.88. The trade was a 0.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 41,356 shares of company stock worth $8,374,584 in the last quarter. 5.63% of the stock is owned by insiders.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $223.37 on Friday. The firm has a market cap of $31.99 billion, a PE ratio of -137.04 and a beta of 1.57. The firm has a fifty day moving average of $202.37 and a 200 day moving average of $215.69. Natera, Inc. has a one year low of $131.81 and a one year high of $256.36.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, topping the consensus estimate of ($0.46) by $0.81. The company had revenue of $665.50 million during the quarter, compared to analyst estimates of $600.68 million. Natera had a negative net margin of 9.05% and a negative return on equity of 14.74%. During the same quarter in the previous year, the firm earned ($0.41) EPS. On average, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced a new collaboration with Diakonos Oncology to use Signatera in a Phase I/II study for refractory melanoma, expanding a key cancer-testing product into another clinical use case and reinforcing its oncology growth story. Article Title
• Positive Sentiment: Canaccord raised its price target on Natera to $250 from $200, signaling stronger confidence in the company’s outlook and helping fuel bullish sentiment. Article Title
• Positive Sentiment: Natera is also drawing attention from investors after commentary calling it a favorite stock idea for the rest of 2026, which adds to the momentum around the name. Article Title

Analysts Set New Price Targets

A number of equities analysts have issued reports on NTRA shares. Evercore reissued an “outperform” rating and set a $270.00 price target on shares of Natera in a research report on Friday, May 8th. JPMorgan Chase & Co. lifted their target price on shares of Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. Wall Street Zen lowered shares of Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, BTIG Research cut their target price on shares of Natera from $260.00 to $250.00 and set a “buy” rating for the company in a report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $256.60.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.